LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

UroGen Pharma Ltd

Închisă

7.34 44.2

Rezumat

Modificarea prețului

24h

Curent

Minim

5.09

Maxim

8.18

Indicatori cheie

By Trading Economics

Venit

-6.3M

-44M

Vânzări

-4.3M

20M

EPS

-0.92

Marjă de profit

-216.466

Angajați

234

EBITDA

-6.2M

-37M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+295.53% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-296M

223M

Deschiderea anterioară

-36.86

Închiderea anterioară

7.34

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

UroGen Pharma Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 mai 2025, 19:39 UTC

Principalele dinamici ale pieței

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Comparație

Modificare preț

UroGen Pharma Ltd Așteptări

Obiectiv de preț

By TipRanks

295.53% sus

Prognoză pe 12 luni

Medie 20.33 USD  295.53%

Maxim 36 USD

Minim 3 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUroGen Pharma Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

7 ratings

5

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

9.625 / 11.64Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Neutral Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.